1/27/2021 8:42:44 AM
Cellectar Gets Orphan Drug Designation From EMA For CLR 131 In Waldenstrom's Macroglobulinemia
11/9/2020 8:48:33 AM
Cellectar Q3 Net Loss Attributable $3.9 Mln Or $0.15/Shr Vs Loss $3.9 Mln Or $0.42/Shr Last Year
7/1/2020 8:13:59 AM
Cellectar Biosciences Appoints John Friend As Chief Medical Officer
6/3/2020 9:06:09 AM
Cellectar Biosciences Reports Pricing Of $20 Mln Underwritten Public Offering
5/26/2020 7:54:32 AM
Cellectar Biosciences Secures FDA Fast Track Designation For CLR 131
1/7/2020 8:21:14 AM
Cellectar Names Igor Grachev Chief Medical Officer
1/6/2020 8:24:31 AM
Cellectar Biosciences Secures Orphan Drug Designation For CLR 131 In Lymphoplasmacytic Lymphoma
9/30/2019 8:41:09 AM
Cellectar Biosciences Presents Data From DLBCL Cohort Of Phase 2 CLOVER-1 Study
7/9/2019 8:38:16 AM
Cellectar Receives FDA Fast Track Designation For CLR 131 In Diffuse Large B-Cell Lymphoma
5/13/2019 8:21:55 AM
Cellectar Receives FDA Fast Track Designation For CLR 131 In Relapsed Or Refractory Multiple Myeloma
11/13/2018 8:50:26 AM
Cellectar Biosciences Q3 Net Loss $5.3 Mln Or $1.65/shr Vs Net Loss $3.5 Mln Or $2.58/shr Prior Year
11/12/2018 8:34:19 AM
Cellectar Reports FDA Grants Exemption To Import Alert For CLR 131 Hematology Studies